{
  "id": 13904615,
  "title": "Kexing Biopharm displays biosimilar pipeline at CPHI Milan",
  "url": "https://urgent.news/2026/10/12/kexing-biopharm-displays-biosimilar-pipeline-at-cphi-milan",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-12T07:51:42.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/kexing-biopharm-displays-biosimilar-pipeline-at-cphi-milan-162626.html"
  },
  "original_language": "en",
  "account": "MILAN, October 10, 2026 - During the CPHI Milan 2026 event from October 6 to 8, Kexing Biopharm (688136.SH) highlighted its expansive global pipeline of innovative drugs and biosimilars. The company interacted with global drug buyers, biotechnology firms, and industry partners. Over the past years, Kexing Biopharm has developed a robust overseas commercialization infrastructure, having secured agreements for over 30 products with various domestic pharmaceutical entities. These products address oncology, autoimmune, and metabolic conditions, with the marketing network reaching nearly 70 countries and regions. Nearly 200 overseas registration applications have also been submitted. Europe stands as a key market, notably for albumin-bound paclitaxel, already approved in the EU, the UK, and other regions. The company is cultivating more than ten high-potential biosimilars for international markets. To enhance its European foothold, Kexing Biopharm has set up a subsidiary in Germany and is advancing plans for subsidiaries in France, Spain, Italy, the United Kingdom, the Netherlands, and other markets, allowing for more responsive service to regional customers and stronger partnerships. Kexing Biopharm's ongoing involvement in European CPHI events has been instrumental in solidifying its regional presence and facilitating face-to-face engagements with local industry collaborators. The core strategic focus of Kexing Biopharm is innovation coupled with internationalization. The showcased pipelines, notably in cancer cachexia, ophthalmic drugs, systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD), attracted considerable interest from attendees due to their targeting of long-term chronic diseases and unmet clinical demands. With three decades of experience in biopharmaceutical manufacturing, Kexing Biopharm boasts a mature production and quality control system. The albumin-bound paclitaxel production line holds EU GMP certification, and the product has been approved in over 40 countries and regions. Moving forward, Kexing Biopharm intends to continue advancing the development and commercialization of high-quality medicines, partnering globally to enhance global health.",
  "summary": "Pharmaceutical developer Kexing Biopharm presented its co developed biosimilar drug pipeline and commercial overseas portfolio at the CPHI Milan 2026 trade exhibition",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}